Fulphila

Fulphila is a biosimilar medication containing pegfilgrastim, used to support the immune system during certain medical treatments. It is administered subcutaneously and is manufactured by Biosimilar Collaborations Ireland Limited.

Fulphila is primarily used to help reduce the risk of infections in patients undergoing chemotherapy. It works by stimulating the production of white blood cells, which are crucial for fighting infections. This medication is often prescribed to support the immune system during cancer treatments.

Common effects of Fulphila may include bone pain, headache, and fatigue. Some patients might experience mild redness or swelling at the injection site. These effects are generally temporary and should be discussed with a healthcare provider if they persist or worsen.

Fulphila should be handled with care and stored as directed. It is important to follow the administration guidelines provided by a healthcare professional. Patients should inform their doctor about any allergies or medical conditions before using this medication.

Fulphila may interact with other medications, including those that affect the immune system. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements may also affect the efficacy of Fulphila.